Evogene (NASDAQ:EVGN) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Evogene Ltd. (NASDAQ:EVGN) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.67 and traded as low as $1.53. Evogene shares last traded at $1.54, with a volume of 16,871 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Evogene in a report on Wednesday. They issued a “sell” rating for the company.

Evogene Stock Down 1.3 %

The company’s 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $2.67. The company has a market capitalization of $8.26 million, a price-to-earnings ratio of -0.34 and a beta of 1.30.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.